Based on these promising studies we report for the first time, clinical proof of concept of the ARd regimen in relapsed/refractory MM patients through a phase I/II clinical trial (NCT02697344) and correlatives analyses’ highlighting the effects of this regimen on Bcl-2 protein dynamics and changes in immune cell populations. The gene discussed is BCL2; the disease is Miyoshi myopathy.